http://www.avibio.com/ AVI BioPharma News and Press Releases Tue, 23 Dec 2008 19:00:00 PDT http://www.avibio.com/pr/pr404.php PORTLAND, OR — December 23, 2008 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced that it learned earlier today that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug (IND) applications filed in November for its two lead products for Marburg and Ebola virus. AVI BioPharma expects to receive written confirmation of the IND clearances from the FDA in early 2009. [more...] Tue, 23 Dec 2008 19:00:00 PDT http://www.avibio.com/pr/pr404.php http://www.avibio.com/pr/pr403.php Composition of Matter Patent for Enhanced Antisense Agent AVI-5126 [more...] Tue, 23 Dec 2008 06:30:00 PDT http://www.avibio.com/pr/pr403.php http://www.avibio.com/pr/pr402.php PORTLAND, OR — December 11, 2008 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that it will present at the public hearing designated to provide advice and comment to the Food and Drug Administration regarding the new priority review voucher (PRV) system. The hearing: “Designating Additions to the Current List of Tropical Diseases in the Food and Drug Administration Amendments Act” is scheduled to take place on December 12, 2008 at the National Transportation Safety Board Boardroom and Conference Center at 429 L'Enfant Plaza, SW, Washington, DC 20594. The public meeting will gather testimony regarding those tropical diseases that should be added to the list of diseases that qualify for consideration for the award of a PRV and the process by which decisions on future additions to the designated listed might be made. [more...] Thu, 11 Dec 2008 06:30:00 PDT http://www.avibio.com/pr/pr402.php